Drug Guide
Labetalol Hydrochloride
Classification
Therapeutic: Antihypertensive
Pharmacological: Beta-adrenergic blocker with alpha-1 blocker activity
FDA Approved Indications
- Management of hypertension
Mechanism of Action
Labetalol is a non-selective beta-adrenergic antagonist with alpha-1 adrenergic blocking activity, which causes vasodilation and decreases blood pressure by reducing heart rate and peripheral resistance.
Dosage and Administration
Adult: Initial dose typically 100 mg twice daily, titrated based on response. Maximum dose may be up to 2400 mg/day in divided doses.
Pediatric: Not commonly used in pediatric populations; consult specific guidelines.
Geriatric: Dose adjustments may be necessary based on renal and hepatic function; start at lower doses.
Renal Impairment: Use caution; may require dose adjustment and monitoring.
Hepatic Impairment: Use with caution; hepatic function should be monitored.
Pharmacokinetics
Absorption: Well absorbed orally.
Distribution: Widely distributed; crosses the blood-brain barrier.
Metabolism: Extensively metabolized in the liver.
Excretion: Excreted in urine and bile.
Half Life: 3 to 6 hours.
Contraindications
- Asthma or other bronchospastic conditions
- Second- or third-degree heart block
- Cardiogenic shock
Precautions
- Use with caution in heart failure, renal impairment, hepatic impairment, and in patients with a history of depression. Monitor blood pressure, heart rate, and respiratory status regularly. Not recommended during pregnancy unless clearly needed; breastfeeding considerations should be discussed.
Adverse Reactions - Common
- Fatigue (Common)
- Dizziness (Common)
- Nausea (Common)
- Bradycardia (Less common)
Adverse Reactions - Serious
- Severe hypotension (Rare)
- Bronchospasm (Rare)
- Liver function abnormalities (Rare)
- Heart failure exacerbation (Rare)
Drug-Drug Interactions
- Other antihypertensives, like calcium channel blockers, nitrates, diuretics, which may enhance hypotensive effects.
- CYP2D6 inhibitors may affect the metabolism of labetalol.
Drug-Food Interactions
- Alcohol may enhance hypotensive effects.
Drug-Herb Interactions
N/ANursing Implications
Assessment: Monitor blood pressure, heart rate, respiratory status, and signs of heart failure.
Diagnoses:
- Risk for ineffective tissue perfusion related to hypotension.
- Impaired gas exchange related to bronchospasm.
Implementation: Administer with meals to decrease orthostatic hypotension. Titrate doses carefully and monitor patient response.
Evaluation: Assess blood pressure and heart rate regularly to evaluate therapeutic effect and adjust dosage accordingly.
Patient/Family Teaching
- Instruct patient to take medication as prescribed and not to stop suddenly.
- Warn about possible side effects like dizziness, fatigue, and bronchospasm.
- Advise to rise slowly from sitting or lying position.
- Inform about possible interactions with other medications and the importance of reporting all current medications.
Special Considerations
Black Box Warnings:
- Use in caution in patients with asthma or other bronchospastic conditions.
Genetic Factors: CYP2D6 poor metabolizers may have increased plasma levels.
Lab Test Interference: May interfere with certain laboratory tests, including liver function tests.
Overdose Management
Signs/Symptoms: Severe hypotension, bradycardia, bronchospasm, loss of consciousness.
Treatment: Supportive care, IV fluids, atropine for bradycardia, vasopressors for hypotension, airway management as needed.
Storage and Handling
Storage: Store at room temperature, 20-25°C (68-77°F).
Stability: Stable under recommended storage conditions.